CIP
MNTA

Convergence Investment Partners’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Convergence Investment Partners’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-38,738
Closed -$655K – 418
2017
Q2 		$655K Buy
+38,738
New +$590K 0.1% 279
2015
Q4 		– Sell
-71,228
Closed -$1.17M – 412
2015
Q3 		$1.17M Buy
+71,228
New +$1.46M 0.13% 234

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Convergence Investment Partners's MNTA Position: Q3 2017 in Review

Convergence Investment Partners sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2017, closing a stake of 38,738 shares — an estimated $655K sold.

Convergence Investment Partners first reported a position in MNTA in Q3 2015 and held it in 2 quarters. The position peaked at $1.17M in Q3 2015. 158 funds tracked by Wall St. Rank hold MNTA as of Q3 2017.

  • Convergence Investment Partners reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Convergence Investment Partners sold 38,738 Momenta Pharmaceuticals, Inc. shares in Q3 2017, an estimated $655K.
  • Convergence Investment Partners first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
  • Convergence Investment Partners's Momenta Pharmaceuticals, Inc. position peaked at $1.17M in Q3 2015.
  • 158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2017.

Based on Convergence Investment Partners's 13F filing for Q3 2017, filed 13 Nov 2017.